You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Antimicrobial Resistance (AMR)

Test Information
Masthead

Enabling Global Health Solutions

Cepheid’s Global Access Program centers on the belief that everyone, everywhere should have access to high quality diagnostic tests. Together with our partners, Cepheid brings rapid molecular testing to communities in low- and middle-income countries, improving patient outcomes and trailblazing standards of care.

Diagnosis is the critical first step in the path to health, linking patients to care, enabling appropriate treatment, and increasing the likelihood of fast recovery. Cepheid’s Global Access Program was established in 2011 to provide equitable access to diagnostic solutions globally through continuous solution innovation, holistic implementation of these solutions, cross-sector partnerships, and advocacy.

Program Goals

Program Pillars

Solution innovation

We embed ourselves in the communities we serve to understand their needs, challenges, and preferences and translate these insights into patient-centric solutions: molecular diagnostic systems, tests, and service and support programs. Diseases are not static, so we continuously challenge ourselves to improve existing offerings and to anticipate what the world will need five to ten years from now.

Holistic implementation of solutions

Instruments and tests alone are not enough, so we strive to provide an ecosystem of awareness and educational initiatives, service, support, and delivery models to strengthen national diagnostic infrastructure.

Cross-sector partnerships

We engage directly with donors, policymakers, governments, NGOs, communities, and patients to ensure our work supports global, national, and local health system and disease elimination goals.

Advocacy

We speak up for policies and public health initiatives that increase access to molecular testing and reduce health disparities.

Program Reach

#timeline-content-8 .stopwatch path { --progress: ${progressBar}$; }

Program History

2006

image Cepheid places first GeneXpert systems

2006

image WHO launches Stop TB Strategy on World TB Day

2006

image Cepheid, FIND, University of Medicine and Dentistry of New Jersey (Rutgers University), and NIAID collaborate to develop Xpert MTB/RIF with a grant from the Bill & Melinda Gates Foundation

2009 - 2010

image Xpert MTB/RIF launches and gets WHO endorsement

2011

image Cepheid officially establishes Global Access Program

2011

image Cepheid and FIND partner on development of Xpert HIV-1 viral load (VL) test for GeneXpert systems to address high rates of TB-HIV co-infection in Global Access countries

2014

image Xpert HPV and Xpert HIV-1 VL tests launch

2014 - 2015

image Cepheid develops Xpert Ebola assay to respond to West African outbreak with funding support from the Paul G. Allen and Bill & Melinda Gates Foundations

2015

image Xpert HIV-1 Qual and HCV VL tests launch

2016

image WHO prequalifies Xpert HIV-1 Qual

2017

image WHO prequalifies Xpert HCV VL, Xpert HIV-1 VL, and Xpert HPV; Xpert MTB/RIF Ultra launches and gets WHO endorsement

2020

image Xpert MTB/XDR launches to detect multidrug-resistant TB with new 10-color multiplexing technology

2020

image Xpert SARS-CoV-2 launches

Global Access Program Today

image 13 tests available under Global Access Program; 7 tests endorsed or pre-qualified by WHO; 6 modular systems with multiple configuration options

Contact Us

·      For media inquiries, contact Darwa.Peterson@cepheid.com.

·      For product and partnerships, please contact <Global Access email>.

·      For regional inquiries, please contact <Global Access email>.

ELIGIBILITY & PRICING

Please visit https://www.finddx.org/pricing/genexpert/ for the latest information.

 

Eligibility

Countries that are currently eligible for Cepheid’s Global Access Program include:

Afghanistan

Ecuador

Macedonia

Sierra Leone

Albania

Egypt

Madagascar

Solomon Islands

Algeria

El Salvador

Malawi

Somalia

Angola

Eritrea

Malaysia

South Africa

Antigua & Barbuda

Estonia

Maldives

Sri Lanka

Argentina

Ethiopia

Mali

St Kitts and Nevis

Armenia

Fiji

Mauritania

St Lucia

Azerbaijan

Gabon

Mauritius

St Vincent & Grenadines

Bangladesh

The Gambia

Mexico

Sudan

Belarus

Gaza Strip

Micronesia

Sudan, South

Belize

Georgia

Moldova

Suriname

Benin

Ghana

Mongolia

Swaziland

Bhutan

Grenada

Montenegro

Syria

Bolivia

Guatemala

Morocco

Tajikistan

Bosnia-Herzegovina

Guinea

Mozambique

Tanzania

Botswana

Guinea, Equatorial

Myanmar

Thailand

Brazil

Guinea-Bissau

Namibia

Timor-Leste

Bulgaria

Haiti

Nauru

Togo

Burkina Faso

Honduras

Nepal

Tonga

Burundi

India

Nicaragua

Tunisia

Cabo Verde

Indonesia

Niger

Turkmenistan

Cambodia

Iraq

Nigeria

Tuvalu

Cameroon

Jamaica

Pakistan

Uganda

Central African Republic

Jordan

Palau

Ukraine

Chad

Kazakhstan

Panama

Uruguay

Chile

Kenya

Papua New Guinea

Uzbekistan

Colombia

Kiribati

Paraguay

Vanuatu

Comoros

Korea, North

Peru

Venezuela

Congo (Democratic Republic of)

Kosovo

Philippines

Vietnam

Congo (Republic of the)

Kyrgyzstan

Romania

Western Sahara

Costa Rica

Lao PDR

Russia

Yemen

Côte d’Ivoire

Latvia

Rwanda

Zambia

Croatia

Lebanon

Samoa

Zimbabwe

Cuba

Lesotho

Sao Tome & Principe

 

Djibouti

Liberia

Senegal

 

Dominica

Libya

Serbia

 

Dominican Republic

Lithuania

Seychelles

 

Within these countries, eligibility for Cepheid’s Global Access Program includes:

  • Governments or government-funded institutions such as health ministries, associated hospitals, armed forces, or prison services in those countries
  • NGOs and United Nations-related organizations working for or in eligible countries such as Partners in Health (PIH) or UNICEF
  • Non-profit organizations such as Médecins Sans Frontières, Save-the-Children, OXFAM and the International Committee of the Red Cross (ICRC)
  • Global health funding mechanisms such as the Global Drug Facility, UNITAID, PEPFAR, USAID and the Global Fund, and agencies based outside the country but supporting implementation locally in the country, such as the U.S. Centers for Disease Control and Prevention and the International Union Against Tuberculosis and Lung Disease
  • On a case-by-case basis, private organizations recognized by a country’s health ministry and whose mission is in line with humanitarian principles

 

Pricing

Please visit https://www.finddx.org/pricing/genexpert/ for the latest pricing information.

Back to Top